BIOLEX AND KRINGLE ANNOUNCE COLLABORATION FOR PRODUCTION OF A NOVEL PROTEIN TARGETING CANCER

Biolex Therapeutics, a protein therapeutics company, and Kringle Pharma, Inc., a biopharmaceutical company developing cancer therapeutics, have formed a collaboration under which Biolex will use its LEX System(TM) for protein expression to create a commercial line for Kringle's NK4 protein. NK4 is currently in preclinical development for the treatment of multiple cancers, and the creation of a commercial line will facilitate scaled-up production of the protein for clinical development and commercialization.

Yahoo News (http://biz.yahoo.com/prnews/051027/clth044.html?.v=30)